CHRD

Across TCGA pan-cancer cohorts, CHRD Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHRD data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CHRD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRD expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, OV, and LUAD are the cancer types where CHRD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
OV	DFS	Median	II,III,IV	0.182	0.541	.011	30	view →
LUAD	OS	Median	III,IV	0.240	0.686	.010	12	view →
SKCM	DFS	Median	III,IV	0.882	0.456	.010	9	view →
SARC	OS	Median	All	0.143	0.745	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHRD–ACC (DFS)

Open the ACC breakdown →